<SEC-DOCUMENT>0001193125-18-288593.txt : 20181001
<SEC-HEADER>0001193125-18-288593.hdr.sgml : 20181001
<ACCEPTANCE-DATETIME>20181001080100
ACCESSION NUMBER:		0001193125-18-288593
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20181001
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181001
DATE AS OF CHANGE:		20181001

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		181095908

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d615984d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): October&nbsp;1, 2018, Japan Standard Time </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-36740</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">77-0357827</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>409 Illinois Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San
Francisco, CA 94158 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">978-1200</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report.) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;1, 2018, Japan Standard Time, FibroGen, Inc. and its collaboration partner, Astellas Pharma Inc., issued a press release in
which they announced that Astellas submitted an application for marketing approval in Japan of roxadustat for the treatment of anemia associated with chronic kidney disease in patients on dialysis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This submission triggers a $15&nbsp;million milestone payment from Astellas to FibroGen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of such press release is furnished as Exhibit&nbsp;99.1 to this report and is incorporated herein by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d615984dex991.htm">Press Release titled &#147;Astellas Submits New Drug Application in Japan of Roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis&#148; dated October&nbsp;
1, 2018 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>FIBROGEN, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: October&nbsp;1, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Michael Lowenstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Lowenstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Legal Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d615984dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g6159841_.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g6159842.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Press Release </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Astellas Submits New Drug Application in Japan of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Roxadustat for The Treatment of Anemia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Associated with Chronic Kidney Disease in Patients on Dialysis </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TOKYO and San Francisco, October</B><B></B><B>&nbsp;1, 2018</B> - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,
&#147;Astellas&#148;) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff, &#147;FibroGen&#148;) today announced that Astellas submitted a New Drug Application (NDA) for marketing approval in Japan of roxadustat (generic name, development code: <FONT
STYLE="white-space:nowrap">ASP1517/FG-4592)</FONT> for the treatment of anemia associated with Chronic Kidney Disease (CKD) in patients on dialysis. The results obtained from four Phase 3 studies conducted in CKD patients on dialysis in Japan
support this NDA submission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased to report the submission of the Japan NDA for roxadustat as a treatment of anemia associated with CKD
in patients on dialysis,&#148; said Bernhardt G. Zeiher, M.D., Chief Medical Officer, Astellas. &#147;We believe roxadustat offers a potential new oral therapeutic option for a condition which can have a debilitating impact on patients with renal
disease.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are excited about this critical advancement as we work together to bring this new therapy to patients with anemia associated with
CKD in Japan,&#148; said K. Peony Yu, M.D., Chief Medical Officer, FibroGen. &#147;We appreciate the joint team&#146;s dedicated effort and commitment to addressing important unmet medical needs of these patients and their physicians.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anemia is a common complication of CKD and is associated with significant morbidity and mortality in dialysis and
<FONT STYLE="white-space:nowrap">non-dialysis</FONT> populations. Anemia is a serious medical condition in which patients have insufficient red blood cells and low levels of hemoglobin (Hb), a protein in red blood cells that carries oxygen to cells
throughout the body. Anemia is associated with increased risk of hospitalization, cardiovascular complications, need for blood transfusion, exacerbation of other serious medical conditions, and death. In addition, anemia frequently causes
significant fatigue, cognitive dysfunction, and decreased quality of life. The more severe the anemia, as measured by lower Hb levels, the greater the health impact on patients. Treatment for anemia in CKD patients is a critical worldwide healthcare
issue that represents a large and growing unmet medical need. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Chronic Kidney Disease (CKD) and Anemia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CKD is estimated affect more than 200&nbsp;million people worldwide<SUP STYLE="font-size:85%; vertical-align:top">*1</SUP> and specifically in Japan, the
prevalence of CKD has increased significantly over time.<SUP STYLE="font-size:85%; vertical-align:top">*2</SUP> Although CKD can occur at any age, it becomes more common in aging populations, and the prevalence is increasing. Anemia is a common
complication of CKD and is associated with significant morbidity and mortality in dialysis and <FONT STYLE="white-space:nowrap">non-dialysis</FONT> populations. In addition, CKD can be both a cause and a consequence of cardiovascular disease and is
now a critical worldwide healthcare issue that represents a large and growing unmet medical need. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Roxadustat </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roxadustat, discovered and developed by FibroGen, is a compound currently in Phase 3 development on a global basis as a potential therapy for anemia associated
with CKD in both patients on dialysis and not on dialysis. Roxadustat is an orally administered small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase activity. HIF is a protein transcription factor that induces the natural
physiological response to conditions of low oxygen, &#147;turning on&#148; erythropoiesis (the process by which red blood cells are produced). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astellas
and FibroGen are collaborating on the development of roxadustat for the potential treatment of anemia in patients with CKD and myelodysplastic syndromes in territories including Japan, Europe, the Commonwealth of Independent States, the Middle East,
and South Africa. FibroGen and AstraZeneca are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in patients with CKD in the U.S., China, and other markets. For information about roxadustat
studies, please visit clinicaltrials.gov at this link: <U> </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>https://clinicaltrials.gov/ct2/results?term=roxadustat&amp;Search=Search</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Astellas </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astellas Pharma Inc., based in Tokyo,
Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at <U>https://</U><U>www.astellas.com/en</U>
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About FibroGen </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc., headquartered in San
Francisco, with subsidiary offices in Beijing and Shanghai, is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF),
connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company&#146;s most advanced product candidate, is an oral small
molecule inhibitor of HIF prolyl hydroxylase activity, completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application (NDA) currently under review in China by the State Drug
Administration (SDA). Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS). Pamrevlumab, an anti-CTGF human monoclonal antibody, is
advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic
cornea in China. For more information, please visit <U>www.fibrogen.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) Ojo, A. Addressing the Global Burden of Chronic Kidney Disease Through
Clinical and Translational Research. <I>Transactions of the American Clinical and Climatological Association</I>. 2014, No.&nbsp;125, p. <FONT STYLE="white-space:nowrap">229-246</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) Nagata M, Ninomiya T, Doi Y, Yonemoto K, Kubo M, Hata J, Tsuruya K, Iida M, Kiyohara Y. <I>Nephrol Dial Transplan</I>t. 2010, Aug, vol. 25, no.8,
2557-2564. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Astellas Cautionary Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are
forward-looking statements about the future performance of Astellas. These statements are based on management&#146;s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and
uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i)&nbsp;changes in general economic conditions and in laws and
regulations, relating to pharmaceutical markets, (ii)&nbsp;currency exchange rate fluctuations, (iii)&nbsp;delays in new product launches, (iv)&nbsp;the inability of Astellas to market existing and new products effectively, (v)&nbsp;the inability of
Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi)&nbsp;infringements of Astellas&#146; intellectual property rights by third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute
an advertisement or medical advice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FibroGen Forward-looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release contains forward-looking statements regarding FibroGen strategy, future plans, and prospects, including statements regarding the development of
the company&#146;s product candidates pamrevlumab and roxadustat, the potential safety and efficacy profile of our product candidates, and our clinical, regulatory, and commercial plans, and those of our partners. These forward-looking statements
include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as &#147;may,&#148; &#147;will&#148;, &#147;should,&#148;
&#147;on track,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;continue&#148; and similar words, although some
forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various
programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2017, and our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarter ended June&nbsp;30, 2018, filed with the Securities and Exchange Commission (SEC), including the risk factors set forth
therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except
as required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts for
inquiries or additional information: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Astellas Pharma Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEL: <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">+81-3-3244-3201</FONT></FONT> FAX: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+81-3-5201-7473</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Karen L. Bergman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 (415) <FONT STYLE="white-space:nowrap">978-1433</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>kbergman@fibrogen.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g6159841_.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g6159841_.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M]U+G0ZF25Z47.4HV7K_D=Q5GAA0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0!Y_X^\"Q:I;RZMIL82_0%I$' F Z_P# OYU$H]4?095F
MDJ,E1JOW>GE_P#QFLS[4A;[QJEL>-B'>HQ\%O+=3+#!&7D;HHIG+.<:<>:3L
MCVGX:>&K33K-[Z;$FI9V$GI$OHOU[G_)I1L>%CLRGB8JE'2*_$] JCR@H *
M"@ H * "@ H * $8E5)"EB!T'4T 8X\26_\ :L>FO:W,5P[8PZK@>^0:=@-"
M]NS90F7[--,H!+>4 2!]"1^E("OI&LV^LPR2VZ2*L;;3Y@ )X]B:-@-&@ H
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M%&WHS@&@"4$, 5((/0B@#D=14'XA6''_ "S!_1J?0#K)O]1)_NFD!R_@,?\
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M!IWL^I6FKI+;V37-HT05PK $,">1D^AH J:C87OB&6WAGMC:643[WWN"[^P
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H % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g6159842.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g6159842.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MYY;/3IT_/T$FU]1+&X-U'+.)%>)I&$>WLH^7KWY!/XT-6(@W*[\_^ 6J1H%
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9 !0 4 % !0 4 % !0 4 % !0 4 % '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
